| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.089 | 0.2 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.091 | 0.2 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | 16-beta-bromoandrosterone | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.2 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | -0.25 | 0.2 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.059 | 0.2 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.33 | 0.2 |